Back to search

University of Minnesota

Mechanistic Insights and Therapeutic Approaches for Chemotherapy-Induced Cardiovascular Toxicity

Abstract

dc:description.abstract

My dissertation project belongs to the rapidly growing interdisciplinary field of cardio-oncology, which integrates cardiology and oncology to understand and mitigate cardiovascular complications induced by cancer treatment. As cancer survivorship continues to improve globally, the burden of treatment-related cardiovascular complications has emerged as a defining challenge. Several cancer therapies cause cardiovascular complications with diverse clinical manifestations, including hypertension, heart failure, arrhythmias, and vascular dysfunction. This work addresses that challenge with the objective of characterizing cardiovascular toxicity induced by chemotherapeutic agents, identifying cardioprotective strategies, elucidating molecular mechanisms and early biomarkers of cardiac injury, and clinically evaluating the vascular consequences associated with endocrine therapies. The work presented in this dissertation spans multiple translational approaches, ranging from cellular and molecular investigations to pharmacokinetic/pharmacodynamic (PK/PD) modeling and clinical vascular assessment, with the ultimate goal of preserving cardiovascular health in cancer survivors. In this thesis, I focused on the cardiovascular adverse events induced by three major categories of cancer therapies, including proteasome inhibitors, anthracyclines, and aromatase inhibitors (AIs). Proteasome inhibitors, particularly carfilzomib (CFZ), are highly effective agents used in the treatment of multiple myeloma (MM) but are associated with significant cardiovascular adverse events, including hypertension, heart failure, and endothelial dysfunction. The mechanisms of CFZ-induced cardiovascular toxicity are not fully understood but endothelial dysfunction is thought to play a central role. Anthracyclines, such as doxorubicin (DOX), remain among the most widely used and effective chemotherapeutic agents across multiple malignancies; however, their clinical utility is limited by dose-dependent cardiotoxicity, which may progress to irreversible cardiomyopathy and heart failure. The precise molecular mechanisms underlying DOX-induced cardiotoxicity are complex and not yet fully elucidated, warranting the application of integrative approaches, including multi-omics analyses and quantitative modeling, to identify and characterize novel biomarkers. AIs are standard endocrine therapies for hormone receptor-positive breast cancer in postmenopausal women and have been increasingly associated with vascular dysfunction and elevated long-term cardiovascular risk, potentially mediated through estrogen depletion and endothelial impairment. It remains unclear whether AI-induced endothelial dysfunction is progressive and whether it is reversible following discontinuation of AIs. In Chapter 1, I will provide the conceptual and scientific foundation for this thesis. I will begin by reviewing the cardiovascular toxicities associated with anticancer therapies, with a focus on anthracyclines, proteasome inhibitors, and AIs, which are particularly pertinent to this thesis, and will discuss the emerging role of endothelial dysfunction in cardio-oncology. In addition, I will highlight the applications of integrated omics technologies and PK/PD modeling in understanding the mechanisms of cardiotoxicity and improving biomarker discovery and risk stratification. Finally, I will summarize current and emerging cardioprotective strategies used in cardio-oncology. In Chapter 2, I determined the direct toxic effects of the proteasome inhibitor CFZ on endothelial cells and evaluated whether sodium-glucose cotransporter-2 (SGLT2) inhibitors can mitigate CFZ-induced endothelial toxicity. Using two endothelial cell types, I demonstrated for the first time that CFZ directly induces endothelial apoptosis and dysfunction, characterized by increased adhesion molecule expression (ICAM-1 and VCAM-1) and dysregulation of Akt, MAPK, p70s6k, and AMP-activated protein kinase (AMPK) signaling pathways. Canagliflozin, but not other SGLT2 inhibitors, protected endothelial cells from CFZ-induced apoptosis via an AMPK-dependent mechanism without interfering with the anticancer effects of CFZ. The findings of this work have been published in Biomedicine and Pharmacotherapy (1). Chapter 3 extends the findings from Chapter 2 by further investigating endoplasmic reticulum (ER) stress and autophagy as downstream mechanisms underlying CFZ-induced cardiovascular toxicity and anticancer effects, as well as the effects of canagliflozin on these pathways using both endothelial and MM cells. CFZ induced ER stress in endothelial and MM cells. In endothelial cells, canagliflozin mitigated CFZ-induced markers of ER stress. Whereas, in MM cells, canagliflozin did not alter CFZ-induced ER stress, but instead further upregulated CFZ-induced ATF-4, and enhanced CFZ-induced JNK and Akt activation. In addition, CFZ induced autophagy in endothelial cells while inhibiting it in MM cells. Canagliflozin abrogated CFZ-induced autophagy in endothelial cells. In contrast to its effects in endothelial cells in Chapter 2, canagliflozin enhanced the cytotoxic effects of CFZ in MM cells. Using an innovative co-culture system, I demonstrated that canagliflozin simultaneously enhanced CFZ-induced apoptosis in MM cells while protecting endothelial cells, highlighting its dual therapeutic potential. The findings of this work have been published in Archives of Toxicology (2). In Chapter 4, I first established a mouse model of chronic DOX-induced cardiotoxicity and employed an integrated multi-omics approach combining transcriptomics and proteomics to comprehensively characterize the molecular mechanisms of chronic DOX-induced cardiotoxicity. This represents the first study to report integrated transcriptomics and proteomics from cardiac tissue samples in response to DOX, and to perform temporal proteomics comparison between two timepoints, in which mice were euthanized at either an early (4 days post-DOX) or delayed (6 weeks post-DOX) time point. Cardiac transcriptomics revealed upregulation of stress responsive genes (Phlda3, Trp53inp1) and circadian regulators (Nr1d1), with downregulation of Apelin and Cd74. qPCR validation confirmed coordinated dysregulation of the cardiac circadian clock. Proteomics identified upregulation of serpina3n, thrombospondin-1, and epoxide hydrolase 1. The integrated omics approach identified significant perturbations in pathways such as p53 signaling, apoptosis, epithelial–mesenchymal transition, oxidative phosphorylation and metabolic pathways. Temporal comparison uncovered dynamic remodeling of cardiac signaling, with early response dominated by inflammatory and apoptotic responses, and delayed response marked by cell cycle and DNA repair pathway activation. Furthermore, Serpina3n/SERPINA3 was confirmed as a cross-strain conserved response to DOX, with cardiac but not hepatic tissue specificity, and plasma SERPINA3 concentrations were significantly elevated 24 hours post-DOX in patients with breast cancer, suggesting it as a clinically translatable early biomarker. The findings of this work have been published in Pharmaceuticals (3). In Chapter 5, I developed a PK/PD model to characterize the dynamic relationship between DOX exposure and growth differentiation factor 15 (GDF15), a stress-responsive cytokine and emerging cardiovascular biomarker, in patients with breast cancer. Using modeling and simulation, I demonstrated that GDF15 increases rapidly following DOX administration, peaking at approximately 8 hours post-infusion, substantially earlier than N-terminal pro-B-type natriuretic peptide (NT-proBNP), which peaked at 34 hours. Baseline GDF15 was positively associated with cumulative DOX dose and BMI. Additionally, simulations revealed cumulative DOX dose-dependent increases in GDF15 and enabled preliminary cardiovascular risk stratification using predefined GDF15 thresholds. Collectively, this work establishes a quantitative framework supporting the hypothesis that GDF15 may serve as an early biomarker of anthracycline-induced cardiotoxicity. The findings of this work have been published in Clinical and Translational Science (4). In Chapter 6, I evaluated endothelial dysfunction longitudinally in breast cancer survivors receiving AI therapy and assessed whether vascular impairment is reversible following treatment discontinuation. I demonstrated that AI therapy is associated with progressive endothelial dysfunction that begins early during treatment and worsens with prolonged exposure. Importantly, endothelial dysfunction did not fully recover following AI discontinuation despite restoration of estradiol levels, suggesting persistent vascular effects of endocrine therapy. The findings of this work have been published in Breast Cancer Research and Treatment (5). To conclude the thesis, I highlighted the conclusions and future research directions to mitigate therapy-induced cardiovascular toxicities in cancer survivors (Chapter 7).

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Dabour, Mohamed Shahen Ali

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Citation
Dabour, Mohamed Shahen Ali. (2026). Mechanistic Insights and Therapeutic Approaches for Chemotherapy-Induced Cardiovascular Toxicity. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/283072.

Chain of custody

source
Harvested from
University of Minnesota
Base URL
conservancy.umn.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Dabour, Mohamed Shahen Ali. Mechanistic Insights and Therapeutic Approaches for Chemotherapy-Induced Cardiovascular Toxicity. 2026. https://hdl.handle.net/11299/283072